CNR-100
Chronic Inflammatory Diseases (e.g., rheumatoid arthritis)
PreclinicalActive
Key Facts
Indication
Chronic Inflammatory Diseases (e.g., rheumatoid arthritis)
Phase
Preclinical
Status
Active
Company
About Canurta
AI‑enabled botanical drug developer targeting ALS and inflammatory diseases.
View full company profileTherapeutic Areas
Other Chronic Inflammatory Diseases (e.g., rheumatoid arthritis) Drugs
| Drug | Company | Phase |
|---|---|---|
| Biosimilar Adalimumab | Richter Gedeon | Phase III / Filed |